Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

62 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Iranian specialists' approach to treatment escalation in multiple sclerosis patients with cognitive impairment.
Ghadiri F, Asadollahzadeh E, Ebadi Z, Sahraian MA, Azimi A, Navardi S, Heidari H, Abna Z, Aboutorabi M, Adibi I, Baghbanian SM, Paybast S, Poursadeghfard M, Hosseini S, Shahmohammadi S, Ghaffari M, Ghalyanchi-Langroodi H, Ghiasian M, Kamali H, Kouchaki E, Mahrabi F, Mohammadianinejad E, Nahayati MA, Moghadasi AN. Ghadiri F, et al. Among authors: baghbanian sm. Curr J Neurol. 2023 Jan 5;22(1):1-7. doi: 10.18502/cjn.v22i1.12610. Curr J Neurol. 2023. PMID: 38011357 Free PMC article.
Iranian specialists' approach to surgery in patients with multiple sclerosis.
Ghadiri F, Ebadi Z, Asadollahzadeh E, Sahraian MA, Azimi A, Navardi S, Heidari H, Abna Z, Aboutorabi M, Adibi I, Baghbanian SM, Paybast S, Poursadeghfard M, Hosseini S, Shahmohammadi S, Ghaffari M, Ghalyanchi-Langroodi H, Ghiasian M, Kamali H, Kouchaki E, Mahrabi F, Mohammadianinejad E, Nahayati MA, Moghadasi AN. Ghadiri F, et al. Among authors: baghbanian sm. Curr J Neurol. 2023 Apr 4;22(2):96-102. doi: 10.18502/cjn.v22i2.13336. Curr J Neurol. 2023. PMID: 38011379 Free PMC article.
Characteristics of COVID-19 in patients with multiple sclerosis.
Ghadiri F, Sahraian MA, Shaygannejad V, Ashtari F, Ghalyanchi Langroodi H, Baghbanian SM, Mozhdehipanah H, Majdi-Nasab N, Hosseini S, Poursadeghfard M, Beladimoghadam N, Razazian N, Ayoubi S, Rezaeimanesh N, Eskandarieh S, Naser Moghadasi A. Ghadiri F, et al. Among authors: baghbanian sm. Mult Scler Relat Disord. 2022 Jan;57:103437. doi: 10.1016/j.msard.2021.103437. Epub 2021 Nov 30. Mult Scler Relat Disord. 2022. PMID: 34896875 Free PMC article.
Epidemiology of familial multiple sclerosis in Iran: a national registry-based study.
Salehi Z, Almasi-Hashiani A, Sahraian MA, Ashtari F, Baghbanian SM, Razazian N, Moghadasi AN, Bayati A, Azimi AR, Beladimoghadam N, Harirchian MH, Poursadeghfard M, Navardi S, Shirkoohi R, Heidari H, Ghaffari M, Eskandarieh S. Salehi Z, et al. Among authors: baghbanian sm. BMC Neurol. 2022 Mar 5;22(1):76. doi: 10.1186/s12883-022-02609-1. BMC Neurol. 2022. PMID: 35248009 Free PMC article.
Prescription trends of disease-modifying treatments for multiple sclerosis in Iran over the past 30 years.
Ghadiri F, Sahraian MA, Baghbanian SM, Ashtari F, Razazian N, Majdinasab N, Poursadeghfard M, Hatamian H, Harirchian MH, Beladimoghadam N, Azimi A, Sharifipour E, Hosseini S, Bayati A, Kamali H, Hosseni Nejad Mir N, Faraji F, Mozhdehipanah H, Modara F, Navardi S, Heidari H, Ayoubi S, Naser Moghadasi A, Eskandarieh S. Ghadiri F, et al. Among authors: baghbanian sm. Mult Scler Relat Disord. 2022 May;61:103777. doi: 10.1016/j.msard.2022.103777. Epub 2022 Mar 27. Mult Scler Relat Disord. 2022. PMID: 35390594
Late-onset multiple sclerosis in Iran: A report on demographic and disease characteristics.
Ghadiri F, Sahraian MA, Razazian N, Ashtari F, Poursadeghfard M, Nabavi SM, Navardi S, Baghbanian SM, Shaygannejad V, Harirchian MH, Beladimoghadam N, Majdinasab N, Hosseini S, Azimi A, Kamali H, Sharifipour E, Hosseini Nejad Mir N, Bayati A, Nahayati MA, Heidari H, Mozhdehipanah H, Ghalyanchi Langroodi H, Jalali N, Ayoubi S, Asadollahzadeh E, Ebadi Z, Eskandarieh S, Naser Moghadasi A. Ghadiri F, et al. Among authors: baghbanian sm. Mult Scler Relat Disord. 2023 Feb;70:104493. doi: 10.1016/j.msard.2022.104493. Epub 2022 Dec 29. Mult Scler Relat Disord. 2023. PMID: 36638768
Comparing infusion-related reactions of the first full dose (600 mg) biosimilar ocrelizumab administration with the standard divided protocol in multiple sclerosis patients: a randomized controlled trial study.
Abbasi Kasbi N, Ghadiri F, Sahraian MA, Nahayati MA, Moghadasi AN, Langroodi HG, Poursadeghfard M, Hosseini S, Heidari H, Baghbanian SM, Kamali H, Ameli Z, Shahmohammadi S, Navardi S. Abbasi Kasbi N, et al. Among authors: baghbanian sm. Acta Neurol Belg. 2024 Feb;124(1):205-212. doi: 10.1007/s13760-023-02366-z. Epub 2023 Sep 15. Acta Neurol Belg. 2024. PMID: 37715074 Clinical Trial.
62 results